Skip to main content
. 2019 Aug 14;3(10):1356–1372. doi: 10.1002/hep4.1413

Figure 3.

Figure 3

OLMALINC expression is responsive to sterols, statins, and LXR agonists in HepG2 cells. (A) OLMALINC and SCD increase expression by RT‐qPCR in a time‐dependent manner under sterol‐depleted conditions supplemented with statin treatment (5% lipoprotein‐deficient media with 5 µM simvastatin and 50 µM mavelonic acid) when compared to sterol‐rich conditions (10% FBS) supplemented with DMSO vehicle control, similarly to SREBP2 and its downstream gene HMGCS1. Each time point was normalized to its DMSO 10% FBS‐treated time point. (B) OLMALINC gene expression increases after 24‐hour treatment of GW3695 (an LXRα and LXRβ agonist) when compared to the DMSO vehicle control in 5% LPDS with 5 µM simvastatin and 50 µM mavelonic acid, as measured by RT‐qPCR. Values are mean ± SD (n = 3) for A and C or mean ± SEM for B (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student t test was used for two groups). Abbreviations: DMSO, dimethyl sulfoxide; HMGCS1, 3‐hydroxy‐3‐methylglutaryl‐coenzyme A synthase 1.